Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial

Medicine and Dentistry

• Cytoreductive Surgery 100%
• Neoadjuvant Chemotherapy 73%
• Overall Survival 21%
• Arm 21%
• Hazard Ratio 15%
• Surgery 10%
• Ovarian Cancer 10%
• Peritoneum Cancer 10%
• Patient 10%
• Neoplasm 5%
• Histology 5%
• Progression Free Survival 5%
• Malignant Neoplasm 5%
• Paclitaxel 5%
• Carboplatin 5%
• Labor 5%
• Analysis 5%
• Clinical Trial 5%
• Survival 5%
• Health 5%